Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine

Zhang, Yanan; Deng, Cheng-Lin; Li, Jiaqi; Li, Na; Zhang, Qiuyan; Ye, Han-Qing; Yuan, Zhiming; Zhang, Bo

doi:10.1128/jvi.00504-19

Cited by 38 publications

(29 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ELISpot assays were performed as previously reported ( 26 ). Briefly, 96-well ELISpot plates were coated with a purified anti-mouse IFN-γ capture antibody (BD ELISPOT Set, USA) and incubated overnight at 4°C.…”

Section: Methodsmentioning

confidence: 99%

Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice

et al. 2021

View full text Add to dashboard Cite

Chikungunya fever is an acute infectious disease that is mediated by the mosquito-transmitted chikungunya virus (CHIKV), for which no licensed vaccines are currently available. Here, we explored several immunization protocols and investigated their immunity and protective effects in mice, with DNA- and virus-like particle (VLP)- vaccines, both alone and in combination. Both DNA and VLP vaccine candidates were developed and characterized, which express CHIKV structural genes (C-E3-E2-6K-E1). Mice were immunized twice, with different protocols, followed by immunological detection and CHIKV Ross challenge. The highest antigen-specific IgG and neutralizing activity were induced by DNA and VLP co-immunization, while the highest cellular immunity was induced by DNA vaccination alone. Although all vaccine groups could protect mice from lethal CHIKV challenge, demonstrated as reduced viral load in various tissues, without weight loss, mice co-immunized with DNA and VLP exhibited the mildest histopathological changes and lowest International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) scores, in comparison to mice with either DNA or VLP vaccination alone. We concluded that co-immunization with DNA and VLP is a promising strategy to inducing better protective immunity against CHIKV infection.

show abstract

Section: Methodsmentioning

confidence: 99%

Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The mutant when grown in BHK cell lines had antigenic properties like those of wild type CHIKV. Vaccination of both immunocompetent and immunocompromised mice resulted in complete protection against CHIKV challenge [ 80 ].…”

Section: Arthritogenic Alphaviral Capsid Protein In Vaccine Designmentioning

confidence: 99%

Arthritogenic Alphavirus Capsid Protein

Rao

Taylor

2021

Life

View full text Add to dashboard Cite

In the past two decades Old World and arthritogenic alphavirus have been responsible for epidemics of polyarthritis, causing high morbidity and becoming a major public health concern. The multifunctional arthritogenic alphavirus capsid protein is crucial for viral infection. Capsid protein has roles in genome encapsulation, budding and virion assembly. Its role in multiple infection processes makes capsid protein an attractive target to exploit in combating alphaviral infection. In this review, we summarize the function of arthritogenic alphavirus capsid protein, and describe studies that have used capsid protein to develop novel arthritogenic alphavirus therapeutic and diagnostic strategies.

show abstract

“…challenged with 3 × 10 7 PFU of WT WNV at 30 days post immunization and monitored for weight loss and survival for 21 days. Viremia was quantified at 1 day and 2 days post challenge by plaque assay in BHK-21 cells as described previously 48,50 , and the limit of detection was 10 2 PFU/ml. The IgG antibody titers were also quantified on days 14 and 28 after challenge.…”

Section: Immunity and Challenge Studiesmentioning

confidence: 99%

A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice

Zhang

et al. 2020

npj Vaccines

Self Cite

View full text Add to dashboard Cite

In our previous study, we have demonstrated in the context of WNV-ΔNS1 vaccine (a replication-defective West Nile virus (WNV) lacking NS1) that the NS1 trans-complementation system may offer a promising platform for the development of safe and efficient flavivirus vaccines only requiring one dose. Here, we produced high titer (10 7 IU/ml) replication-defective Japanese encephalitis virus (JEV) with NS1 deletion (JEV-ΔNS1) in the BHK-21 cell line stably expressing NS1 (BHK NS1) using the same strategy. JEV-ΔNS1 appeared safe with a remarkable genetic stability and high degrees of attenuation of in vivo neuroinvasiveness and neurovirulence. Meanwhile, it was demonstrated to be highly immunogenic in mice after a single dose, providing similar degrees of protection to SA14-14-2 vaccine (a most widely used live attenuated JEV vaccine), with healthy condition, undetectable viremia and gradually rising body weight. Importantly, we also found JEV-ΔNS1 induced robust cross-protective immune responses against the challenge of heterologous West Nile virus (WNV), another important member in the same JEV serocomplex, accounting for up to 80% survival rate following a single dose of immunization relative to mock-vaccinated mice. These results not only support the identification of the NS1-deleted flavivirus vaccines with a satisfied balance between safety and efficacy, but also demonstrate the potential of the JEV-ΔNS1 as an alternative vaccine candidate against both JEV and WNV challenge.

show abstract

Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine

Cited by 38 publications

References 53 publications

Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice

Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice

Arthritogenic Alphavirus Capsid Protein

A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice

Contact Info

Product

Resources

About